Patients Refraining from Seeking Medical Care and the Collapse of the Healthcare System Due to the Spread of COVID-19
First written in FY2020. 3 of 11 entries say "Mitigated", first in FY2022. Latest entry: FY2024-Q1.
Vital Ksk Holdings moved to the "Worse" side of this theme in 2020, 3 years before the typical company in this theme (2023).
The whole theme swung hardest in 2022: 3 of 10 companies on the "Worse" side.
4 other companies' latest entry also says "Mitigated".
- FY2024-Q1MitigatedAnnual report
「As the number of prescriptions accepted increased due to greater movement of people and other factors following the reclassification of COVID-19 as a Category 5 disease under the Infectious Diseases Control Law」
It states that the number of prescriptions accepted by the pharmacy business increased following the reclassification of COVID-19 as a Category 5 disease and the increase in movement of people, partially easing the impact of the decline in demand caused by patients refraining from seeking medical care and other factors. - FY2023-Q1MitigatedAnnual report
「As it gradually recovers from the impact of patients refraining from seeking medical care and other factors amid the COVID-19 pandemic」
It states that pharmaceutical demand is gradually recovering, although the impact of patients refraining from seeking medical care and other factors amid the COVID-19 pandemic remains. - FY2022MitigatedAnnual report
「In the fiscal year ended March 2022, pharmaceutical demand recovered more than expected, although it did not reach pre-pandemic levels.」
It states that pharmaceutical demand recovered more than expected, although it remained below pre-pandemic levels, in response to the decline in demand caused by patients refraining from seeking medical care and other factors. - FY2022-Q3Progress in the recovery of demandAnnual report
「Although demand for pharmaceuticals declined significantly in the previous fiscal year due to patients refraining from seeking medical care and postponing treatments such as surgery as a result of the spread of COVID-19, demand has recovered during the nine months ended the third quarter, exceeding our forecast although remaining below pre-pandemic levels.」
It states that although the impact of the decline in demand caused by COVID-19 remains, pharmaceutical demand recovered more than originally expected. - FY2022-Q2Progress in the recovery of demandAnnual report
「Although demand for pharmaceuticals declined significantly in the previous fiscal year due to patients refraining from seeking medical care and postponing treatments such as surgery as a result of the spread of COVID-19, demand has recovered during the current consolidated cumulative period to a level exceeding our forecast, although it remains below pre-pandemic levels.」
It states that pharmaceutical demand recovered more than expected, although it remained below pre-pandemic levels. - FY2022-Q1Gradual recovery in demandAnnual report
「Demand for pharmaceuticals fell sharply in the previous fiscal year due to reduced patient visits and postponed treatments such as surgery resulting from the spread of COVID-19, but recovered gradually during the cumulative consolidated period under review.」
Although the effects of reduced patient visits and other factors related to COVID-19 remained, pharmaceutical demand, which had fallen sharply in the previous fiscal year, recovered gradually during the cumulative period through the quarter under review. - FY2021WorsenedAnnual report
「In the fiscal year ended March 2021, demand for pharmaceuticals fell sharply as patients refrained from seeking medical care and postponed treatments such as surgery due to the spread of COVID-19. Although COVID-19 vaccinations began in Japan, the timing of containment remained difficult to predict. Accordingly, the company expected the effects of COVID-19 to continue in the fiscal year ending March 2022, with pharmaceutical demand not recovering significantly and remaining at a level comparable to that in the fiscal year ended March 2021.」
The company confirmed a decline in demand resulting from reduced patient visits and postponed treatments in full-year results and indicated that demand was not expected to recover significantly in the fiscal year ending March 2022. - FY2021-Q3MaterialisedAnnual report
「In the pharmaceutical wholesale business, demand for pharmaceuticals fell sharply as patients refrained from seeking medical care and postponed treatments such as surgery due to the spread of COVID-19. Our group expected the spread of COVID-19 to move toward containment and conditions to gradually return to normal after the state of emergency was lifted, but patients continued to refrain from seeking medical care and demand for pharmaceuticals has not recovered.」
The company reports that the sharp decline in pharmaceutical demand caused by reduced patient visits and postponed treatments has continued and that demand has not recovered. - FY2021-Q2WorsenedAnnual report
「COVID-19 is currently spreading again, and the timing of containment remains uncertain. Consequently, it is difficult to reasonably estimate the amount of its impact on business performance.」
The company states that the resurgence of infections and increased uncertainty over the timing of containment have made it difficult to reasonably estimate the impact on business performance. - FY2021-Q1MaterialisedAnnual report
「However, patients continued to refrain from seeking medical care even after the state of emergency was lifted, and major changes have occurred in healthcare delivery and patient behavior, including the development of systems at medical institutions to treat patients infected with COVID-19, an increase in long-term prescriptions, and the spread of online consultations. In addition, during the spread of COVID-19, our group gave top priority to its social mission of ensuring a stable supply of pharmaceuticals and supplied pharmaceuticals through a system focused on logistics using rotating shifts, while suspending sales activities.」
Contrary to the containment and normalization expected at the end of the previous fiscal year, patients continued to refrain from seeking medical care, and changes in healthcare delivery and patient behavior and their impact on the business actually emerged. The company states that the timing of containment remains uncertain due to the resurgence of infections. - FY2020First statedAnnual report
「If the spread of COVID-19 continues for an extended period, resulting in patients refraining from seeking medical care and the collapse of the healthcare system, it may affect business performance.」
The prolonged spread of COVID-19, reduced patient visits and the collapse of the healthcare system are identified as new risks to business performance.